Meta-Analysis of Digoxin Use and Risk of Mortality in Patients With Atrial Fibrillation

American Journal of Cardiology

Volumn 115, Issue 7, 2015, Pages 901-906

  Ouyang, Ai Jun ^a   Lv, Yan Ni ^a   Zhong, Hai Li ^a   Wen, Jin Hua ^a   Wei, Xiao Hua ^a   Peng, Hong Wei ^a   Zhou, Jian ^a   Liu, Li Li ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; ANTIARRHYTHMIC AGENT;

ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; HAZARD RATIO; HEART FAILURE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; CAUSE OF DEATH; MORTALITY; RISK FACTOR; SURVIVAL RATE; TRENDS;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; DIGOXIN; HUMANS; RISK FACTORS; SURVIVAL RATE;

EID: 84922815761     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.01.013     Document Type: Article

References (30)

1. 1 Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I.C., Al-Attar, N., Hindricks, G., Prendergast, B., Heidbuchel, H., Alfieri, O., Angelini, A., Atar, D., Colonna, P., De Caterina, R., De Sutter, J., Goette, A., Gorenek, B., Heldal, M., Hohloser, S.H., Kolh, P., Le Heuzey, J.Y., Ponikowski, P., Rutten, F.H., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31 (2010), 2369–2429.
2. 2 January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cleveland, J.C. Jr., Cigarroa, J.E., Conti, J.B., Ellinor, P.T., Ezekowitz, M.D., Field, M.E., Murray, K.T., Sacco, R.L., Stevenson, W.G., Tchou, P.J., Tracy, C.M., Yancy, C.W., 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive Summary: a report of the American college of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130 (2014), 2071–2104.
3. 3 The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity. N Engl J Med 336 (1997), 525–533.
4. 4 Rathore, S.S., Curtis, J.P., Wang, Y., Bristow, M.R., Krumholz, H.M., Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003), 871–878.
5. 5 Chan, K.E., Lazarus, J.M., Hakim, R.M., Digoxin associates with mortality in ESRD. J Am Soc Nephrol 21 (2010), 1550–1559.
6. 6 Turakhia, M.P., Santangeli, P., Winkelmayer, W.C., Xu, X., Ullal, A.J., Than, C.T., Schmitt, S., Holmes, T.H., Frayne, S.M., Phibbs, C.S., Yang, F., Hoang, D.D., Ho, P.M., Heidenreich, P.A., Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol 64 (2014), 660–668.
7. 7 Shah, M., Avgil Tsadok, M., Jackevicius, C.A., Essebag, V., Behlouli, H.L., Pilote, L., Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol 114 (2014), 401–406.
8. 8 Mulder, B.A., Van Veldhuisen, D.J., Crijns, H.J., Tijssen, J.G., Hillege, H.L., Alings, M., Rienstra, M., Van den Berg, M.P., Van Gelder, I.C., Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm 11 (2014), 1543–1550.
9. 9 Rodríguez-Mañero, M., Otero-Raviña, F., García-Seara, J., Zugaza-Gurruchaga, L., Rodríguez-García, J.M., Blanco-Rodríguez, R., Turrado Turrado, V., Fernández-Villaverde, J.M., Vidal-Pérez, R.C., González-Juanatey, J.R., Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR study. Rev Esp Cardiol 67 (2014), 890–897.
10. 10 Whitbeck, M.G., Charnigo, R.J., Khairy, P., Ziada, K., Bailey, A.L., Zegarra, M.M., Shah, J., Morales, G., Macaulay, T., Sorrell, V.L., Campbell, C.L., Gurley, J., Anaya, P., Nasr, H., Bai, R., Di Biase, L., Booth, D.C., Jondeau, G., Natale, A., Roy, D., Smyth, S., Moliterno, D.J., Elayi, C.S., Increased mortality among patients taking digoxin–analysis from the AFFIRM study. Eur Heart J 34 (2013), 1481–1488.
11. 11 Gheorghiade, M., Fonarow, G.C., van Veldhuisen, D.J., Cleland, J.G., Butler, J., Epstein, A.E., Patel, K., Aban, I.B., Aronow, W.S., Anker, S.D., Ahmed, A., Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 34 (2013), 1489–1497.
12. 12 Friberg, L., Hammar, N., Rosenqvist, M., Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart 96 (2010), 275–280.
13. 13 Georgiopoulou, V.V., Kalogeropoulos, A.P., Giamouzis, G., Agha, S.A., Rashad, M.A., Waheed, S., Laskar, S., Smith, A.L., Butler, J., Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail 2 (2009), 90–97.
14. 14 Fauchier, L., Grimard, C., Pierre, B., Nonin, E., Gorin, L., Rauzy, B., Cosnay, P., Babuty, D., Charbonnier, B., Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 103 (2009), 248–254.
15. 15 Gjesdal, K., Feyzi, J., Olsson, S.B., Digitalis: a dangerous drug in atrial fibrillation? an analysis of the SPORTIF III and V data. Heart 94 (2008), 191–196.
16. 16 Hallberg, P., Lindbäck, J., Lindahl, B., Stenestrand, U., Melhus, H., Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 63 (2007), 959–971.
17. 17 Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., Moher, D., Becker, B.J., Sipe, T.A., Thacker, S.B., Meta-Analysis of Observational Studies in Epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
18. 18 Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp. Accessed on October 8, 2012.
19. 19 Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
20. 20 Thummel, K.E., Shen, D.D., Design and optimization of dosage regime. Pharmacologic data. Hardman, J.G., Kimbird, L.E., (eds.) Goodman and Gilman's the Pharmacological Basis of Therapeutics, 2001, McGraw Hill, New York.
21. 21 Davi, G., Patrono, C., Platelet activation and atherothrombosis. N Engl J Med 357 (2007), 2482–2494.
22. 22 Schwartz, A., Whitmer, K., Grupp, G., Grupp, I., Adams, R.J., Lee, S.W., Mechanism of action of digitalis: is the Na,K-ATPase the pharmacological receptor?. Ann N Y Acad Sci 402 (1982), 253–271.
23. 23 Chirinos, J.A., Castrellon, A., Zambrano, J.P., Jimenez, J.J., Jy, W., Horstman, L.L., Willens, H.J., Castellanos, A., Myerburg, R.J., Ahn, Y.S., Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm 2 (2005), 525–529.
24. 24 Chang, S.S., Chang, K.C., Wang, Y.C., Muo, C.H., Pai, P.Y., Chang, C.B., Li, C.Y., Sung, F.C., Digoxin use is associated with increased risk of stroke in patients with non-valvular atrial fibrillation–a nationwide population-based cohort study. Int J Cardiol 169 (2013), e26–e27.
25. 25 McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M.A., Jaarsma, T., Køber, L., Lip, G.Y., Maggioni, A.P., Parkhomenko, A., Pieske, B.M., Popescu, B.A., Rønnevik, P.K., Rutten, F.H., Schwitter, J., Seferovic, P., Stepinska, J., Trindade, P.T., Voors, A.A., Zannad, F., Zeiher, A., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 (2012), 1787–1847.
26. 26 Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr., Drazner, M.H., Fonarow, G.C., Geraci, S.A., Horwich, T., Januzzi, J.L., Johnson, M.R., Kasper, E.K., Levy, W.C., Masoudi, F.A., McBride, P.E., McMurray, J.J., Mitchell, J.E., Peterson, P.N., Riegel, B., Sam, F., Stevenson, L.W., Tang, W.H., Tsai, E.J., Wilkoff, B.L., 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
27. 27 Packer, M., Gheorghiade, M., Young, J.B., Costantini, P.J., Adams, K.F., Cody, R.J., Smith, L.K., Van Voorhees, L., Gourley, L.A., Jolly, M.K., Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329 (1993), 1–7.
28. 28 Guyatt, G.H., Sullivan, M.J., Fallen, E.L., Tihal, H., Rideout, E., Halcrow, S., Nogradi, S., Townsend, M., Taylor, D.W., A controlled trial of digoxin in congestive heart failure. Am J Cardiol 61 (1988), 371–375.
29. 29 Binder, L., Fredrickson, L., Poisonings in laboratory personnel and health care professionals. Am J Emerg Med 9 (1991), 11–15.
30. 30 Englund, G., Hallberg, P., Artursson, P., Michaëlsson, K., Melhus, H., Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med, 2, 2004, 8.